In the Diabetes study, Xu, Shalev and colleagues did a global proteomics study analysis of serum samples from Shalev’s adult study both at baseline and at one year of receiving verapamil or a placebo.

At 24 weeks, 56% of adults receiving paltusotine had an IGF-1 at or below the upper limit of normal compared with 5% of the placebo group (P < .0001).